title: Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil.
abstract: Haematopoietic colony-stimulating factors are used frequently to moderate myelotoxicity, but administration of granulocyte-colony-stimulating factor (G-CSF) prior to chemotherapy actually may worsen the toxic effects on bone marrow. This is important in the design of clinical cancer treatment protocols. Previously, we found that rosiglitazone may protect granulocyte-macrophage progenitor cells (CFU-GM) against damage caused by a single dose of 5-fluorouracil (5-FU). Our new studies are designed to evaluate whether rosiglitazone has similar beneficial effects on bone marrow preservation when administered concurrently with repeated, daily doses of 5-FU while restricting regeneration time. Myelotoxicity characterized by the decrease in cellularity, frequency of granulocyte-macrophage progenitor cells and CFU-GM content of femoral bone marrow in mice. Five-day oral rosiglitazone pre-treatment decreased the susceptibility of granulocyte-macrophage progenitors to 5-FU damage. Significantly, more CFU-GM cells survived after the single intraperitoneal dose of 5-FU (100 mg kg(-1)). The increased frequency of CFU-GM cells with their intensive proliferation allowed faster restoration of the damaged CFU-GM compartment than was seen in the case of repeated daily administration of the cytostatic drug (25 or 50 mg kg(-1)) together with rosiglitazone for 7 consecutive days. The expansion of the CFU-GM compartment was 3 times and 50 times greater in the combined-treated mice than in their counterparts treated with repeated doses of 5-FU alone, although differences in absolute neutrophil counts were not significant. In conclusion, our results indicated that rosiglitazone has protective effects on bone marrow progenitor cells even after daily 5-FU treatment but further studies are warranted to evaluate the optimal treatment schedules.
authors.affiliation: Department of Pharmacology and Pharmacotherapy, Medical and Health Science Center, University of Debrecen, Nagyerdei krt. 98., H-4032 Debrecen, Hungary.
authors.forename: Katayoun
authors.initials: K
authors.lastname: Djazayeri
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Szilvássy
authors.forename: Klára
authors.initials: K
authors.lastname: Benko
authors.forename: Bernadett
authors.initials: B
authors.lastname: Rózsa
authors.forename: Boglárka
authors.initials: B
authors.lastname: Szabó
authors.forename: A József
authors.initials: AJ
authors.lastname: Szentmiklósi
authors.forename: Ilona
authors.initials: I
authors.lastname: Benko
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000633:toxicity*; D001855:Bone Marrow Diseases / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D001861:Bone Regeneration / Q000187:drug effects; D005260:Female; D005472:Fluorouracil / Q000633:toxicity*; D006098:Granulocytes / Q000187:drug effects; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007958:Leukocyte Count; D008264:Macrophages / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009504:Neutrophils / Q000187:drug effects; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D005472:Fluorouracil